Wednesday, November 7, 2012


A late breaking clinical trial assessing chelation therapy (TACT) as a treatment for patients with previous heart attacks showed a significant reduction in subsequent cardiac events, especially the need for cardiac surgery. Intravenous EDTA chelation therapy has been controversial for many years. Numerous studies by proponents of the therapy have shown benefit. Several small clinical trials by cardiovascular surgeons looking at test results have been negative. TACT is the first study to examine solid cardiac events such as death, heart attacks, strokes, the need for cardiac surgery and hospitalization for uncontrolled angina. 170/ patients were given 55,222 infusions at 134 centers in the US and Canada in a randomized, placebo controlled format. The conclusions were that chelation was very safe and that EDTA chelation showed a statistically significant reduction in cardiac events, especially in the need for revascularization surgery (bypass, and angioplasty with stents). Further study was encouraged to confirm the results and to explore the mechanism of action. or

No comments: